Publications by authors named "Chaun-Shu Chen"
Anticancer Res
March 2023
Article Synopsis
- Immune checkpoint inhibitors (ICIs) like atezolizumab and pembrolizumab are increasingly used to treat advanced urothelial carcinoma (aUC), but their optimal use with chemotherapy remains debated.
- A study analyzed 74 aUC patients treated with these ICIs to identify clinical factors affecting outcomes, finding that chemotherapy response and specific health indicators (like liver metastases) significantly influenced disease progression and survival rates.
- Key results indicated that poor responses to chemotherapy were linked to worse outcomes with ICIs, while better ICI responses correlated with improved survival, emphasizing the importance of evaluating individual patient factors.
